CADL — CANDEL THERAPEUTICS INC

Ownership history in Birchview Capital, LP  ·  5 quarters on record

This page tracks every 13F SEC filing in which Birchview Capital, LP reported a position in CANDEL THERAPEUTICS INC (CADL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.42% (2024 Q4)
Avg. % of fund
0.29%
First filed
2024 Q4
Last filed
2025 Q4
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 60,000 — 0% 0.20% $339K $5.65
2025 Q3 UNCHANGED 60,000 — 0% 0.23% $306K $5.10
2025 Q2 UNCHANGED 60,000 — 0% 0.30% $304K $5.06
2025 Q1 UNCHANGED 60,000 — 0% 0.29% $339K $5.65
2024 Q4 INITIATED 60,000 — — 0.42% $521K $8.68
% of Fund (quarterly)    CADL price (monthly, adj. close)

Other funds also holding CADL

As of 2025 Q4 — sorted by position size

ACORN CAPITAL ADVISORS, LLC 4.94% Halter Ferguson Financial Inc. 0.93% Portolan Capital Management, LLC 3Y 7Y 0.51% Sands Capital Alternatives, LLC 3Y 0.44% Torrey Growth & Income Advisors 0.13% Tanager Wealth Management LLP 3Y 0.11% Boreal Capital Management LLC 0.07% Taylor Financial Group, Inc. 0.05% BRIDGEWAY CAPITAL MANAGEMENT, LLC 3Y 7Y 0.01% Stratos Wealth Advisors, LLC 3Y 7Y 0.01%
← Back to Birchview Capital, LP Holdings